Bristol-Myers Squibb Company (BMY): Price and Financial Metrics


Bristol-Myers Squibb Company (BMY)

Today's Latest Price: $60.03 USD

0.61 (-1.01%)

Updated Oct 21 6:40pm

Add BMY to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BMY Stock Summary

  • Bristol Myers Squibb Co's market capitalization of $135,303,696,139 is ahead of 98.64% of US-listed equities.
  • BMY's went public 34.83 years ago, making it older than 92.9% of listed US stocks we're tracking.
  • The volatility of Bristol Myers Squibb Co's share price is greater than that of only 1.11% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Bristol Myers Squibb Co, a group of peers worth examining would be TXN, AMGN, SNY, LLY, and AZN.
  • Visit BMY's SEC page to see the company's official filings. To visit the company's web site, go to www.bms.com.

BMY Stock Price Chart Interactive Chart >

Price chart for BMY

BMY Price/Volume Stats

Current price $60.03 52-week high $68.34
Prev. close $60.64 52-week low $45.76
Day low $59.95 Volume 8,004,800
Day high $60.75 Avg. volume 13,869,034
50-day MA $60.66 Dividend yield 3%
200-day MA $60.32 Market Cap 135.83B

Bristol-Myers Squibb Company (BMY) Company Bio


Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular. The company was founded in 1887 and is based in New York, New York.


BMY Latest News Stream


Event/Time News Detail
Loading, please wait...

BMY Latest Social Stream


Loading social stream, please wait...

View Full BMY Social Stream

Latest BMY News From Around the Web

Below are the latest news stories about Bristol Myers Squibb Co that investors may wish to consider to help them evaluate BMY as an investment opportunity.

Bristol Myers wins FDA OK for mesothelioma drug combo treatment

Bristol Myers Squibb (BMY) says it received Food and Drug Administration approval for the drug combination of Opdivo and Yervoy for use in treatment of adults with malignant pleural mesothelioma.The approval is based on a pre-specified interim analysis from a phase 3 trial in which Opdivo plus Yervoy demonstrated superior...

Seeking Alpha | October 2, 2020

Bristol Myers Squibb Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--BMS Announces Update on CheckMate -915 Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo in Resected High-Risk Melanoma Patients

Business Wire | October 2, 2020

UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026

WASHINGTON & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #UNCF--UNCF, Bristol Myers Squibb Announce Second Cohort of the Ernest E. Just Postgraduate Fellowship and Extension of Partnership Through 2026

Business Wire | October 2, 2020

Rep. Katie Porter ripped into pharma executive Mark Alles for repeated price hikes on a cancer drug Revlimid

Summary List Placement Rep. Katie Porter grilled Celgene CEO Mark Alles Wednesday over price hikes on a cancer drug, which she said resulted in a half-million bonus for the pharma executive. Alles appeared before the House Oversight Committee alongside the CEOs of Teva and Bristol-Myers Squibb as part of a House investigation into the pricing of Teva's Multiple Sclerosis drug Copaxone and Bristol-Myers Squibb's multiple myeloma drug Revlimid. Alles served as CEO of Celgene before it was acquired by Bristol Myers Squibb in 2019. "Since launching Revlimid in 2005, Celgene raised the price of the drug 22 times, from $215 per pill to $719 per pill," according to documents from House Oversight Committee Chairwoman Carolyn Maloney . "After Bristol Myers Squibb obtained the rights to Revlimid ...

Business Insider | October 1, 2020

Bristol Myers Squibb beats investor claims over cancer drug trial

A Manhattan federal judge has dismissed a shareholder suit against Bristol Myers Squibb, finding that investors did not plausibly allege the pharmaceutical company's description of a 2015 drug trial was misleading or that the industry had a standard definition for a key…

Reuters | October 1, 2020

Read More 'BMY' Stories Here

BMY Price Returns

1-mo 2.93%
3-mo 4.55%
6-mo -2.10%
1-year 12.98%
3-year 3.11%
5-year 6.09%
YTD -3.60%
2019 27.74%
2018 -12.90%
2017 7.71%
2016 -13.49%
2015 19.26%

BMY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BMY Dividend History

Continue Researching BMY

Here are a few links from around the web to help you further your research on Bristol Myers Squibb Co's stock as an investment opportunity:

Bristol Myers Squibb Co (BMY) Stock Price | Nasdaq
Bristol Myers Squibb Co (BMY) Stock Quote, History and News - Yahoo Finance
Bristol Myers Squibb Co (BMY) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7454 seconds.